Cargando…

Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia

BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing one-third of pediatric cancers. Thymidine kinase-1 (TK-1) is expressed in proliferating cells so elevated TK-1 indicates active tumor growth. OBJECTIVE: To study the clinical significance of TK-1 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagag, Adel A., Saad, Mohamed A., Mohamed, Sohair A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418086/
https://www.ncbi.nlm.nih.gov/pubmed/25992345
http://dx.doi.org/10.4103/2278-330X.155675
_version_ 1782369435423604736
author Hagag, Adel A.
Saad, Mohamed A.
Mohamed, Sohair A.
author_facet Hagag, Adel A.
Saad, Mohamed A.
Mohamed, Sohair A.
author_sort Hagag, Adel A.
collection PubMed
description BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing one-third of pediatric cancers. Thymidine kinase-1 (TK-1) is expressed in proliferating cells so elevated TK-1 indicates active tumor growth. OBJECTIVE: To study the clinical significance of TK-1 in children with ALL. PATIENTS AND METHODS: This study was carried out on 40 children with newly diagnosed ALL who were admitted to Oncology Unit, Pediatric department, Tanta University (26 males and 14 females) with their ages ranged from 4 to 10 years and 30 healthy children of matched age and sex as a control group. For all patients the following were done: Complete blood picture, bone marrow examination, immunophenotyping and TK-1 serum levels. RESULTS: Mean TK-1 level was significantly higher in patients at diagnosis than controls and significantly higher in patients with unfavorable outcome than patients with favorable outcome. Mean TK-1 level was significantly higher in patients in relapse than patients in remission and controls. No significant differences in mean TK-1 level between patients in remission and controls. There were statistically significant differences in disease free survival and overall survival between patients with favorable and unfavorable outcome. CONCLUSION: From this study we concluded that TK is a helpful marker in diagnosis and follow-up of patients with ALL. RECOMMENDATIONS: Thymidine kinase-1 should be routinely assessed at diagnosis and during follow-up in ALL patients for better diagnostic and prognostic assessment and should be taken in consideration in designing future therapeutic strategies based on patients-specific risk factors.
format Online
Article
Text
id pubmed-4418086
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44180862015-05-19 Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia Hagag, Adel A. Saad, Mohamed A. Mohamed, Sohair A. South Asian J Cancer MINI SYMPOSIUM: PEDIATRIC ONCOLOGY BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing one-third of pediatric cancers. Thymidine kinase-1 (TK-1) is expressed in proliferating cells so elevated TK-1 indicates active tumor growth. OBJECTIVE: To study the clinical significance of TK-1 in children with ALL. PATIENTS AND METHODS: This study was carried out on 40 children with newly diagnosed ALL who were admitted to Oncology Unit, Pediatric department, Tanta University (26 males and 14 females) with their ages ranged from 4 to 10 years and 30 healthy children of matched age and sex as a control group. For all patients the following were done: Complete blood picture, bone marrow examination, immunophenotyping and TK-1 serum levels. RESULTS: Mean TK-1 level was significantly higher in patients at diagnosis than controls and significantly higher in patients with unfavorable outcome than patients with favorable outcome. Mean TK-1 level was significantly higher in patients in relapse than patients in remission and controls. No significant differences in mean TK-1 level between patients in remission and controls. There were statistically significant differences in disease free survival and overall survival between patients with favorable and unfavorable outcome. CONCLUSION: From this study we concluded that TK is a helpful marker in diagnosis and follow-up of patients with ALL. RECOMMENDATIONS: Thymidine kinase-1 should be routinely assessed at diagnosis and during follow-up in ALL patients for better diagnostic and prognostic assessment and should be taken in consideration in designing future therapeutic strategies based on patients-specific risk factors. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4418086/ /pubmed/25992345 http://dx.doi.org/10.4103/2278-330X.155675 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle MINI SYMPOSIUM: PEDIATRIC ONCOLOGY
Hagag, Adel A.
Saad, Mohamed A.
Mohamed, Sohair A.
Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title_full Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title_fullStr Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title_full_unstemmed Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title_short Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
title_sort clinical significance of thymidine kinase in egyptian children with acute lymphoblastic leukemia
topic MINI SYMPOSIUM: PEDIATRIC ONCOLOGY
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418086/
https://www.ncbi.nlm.nih.gov/pubmed/25992345
http://dx.doi.org/10.4103/2278-330X.155675
work_keys_str_mv AT hagagadela clinicalsignificanceofthymidinekinaseinegyptianchildrenwithacutelymphoblasticleukemia
AT saadmohameda clinicalsignificanceofthymidinekinaseinegyptianchildrenwithacutelymphoblasticleukemia
AT mohamedsohaira clinicalsignificanceofthymidinekinaseinegyptianchildrenwithacutelymphoblasticleukemia